CG
OKUR

Carlyle Group’s OnKure Therapeutics OKUR Stock Holding History

Carlyle Group’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Hold
269,895
– – 0.01% 11
2026
Q1 		$1.12M Hold
269,895
– – 0.01% 13
2025
Q4 		$772K Hold
269,895
– – 0.01% 14
2025
Q3 		$742K Hold
269,895
– – 0.02% 15
2025
Q2 		$642K Hold
269,895
– – 0.01% 18
2025
Q1 		$1.16M Hold
269,895
– – 0.03% 19
2024
Q4 		$2.33M Sell
269,895
-1
-0% -$15 0.06% 19
2024
Q3 		$4.53M Hold
269,896
– – 0.48% 12
2024
Q2 		$4.16M Hold
269,896
– – 0.39% 15
2024
Q1 		$4.45M Hold
269,896
– – 0.28% 17
2023
Q4 		$4.32M Hold
269,896
– – 0.21% 16
2023
Q3 		$20.5M Hold
269,896
– – 0.89% 11
2023
Q2 		$17.7M Buy
269,896
+62,500
+30% +$5.04M 0.63% 11
2023
Q1 		$12.2M Buy
+207,396
New +$7.52M 0.37% 14

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Carlyle Group's OKUR Position: Q2 2026 in Review

Carlyle Group held its OnKure Therapeutics (OKUR) position steady in Q2 2026 at 269,895 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #11.

Carlyle Group first reported a position in OKUR in Q1 2023 and has held it in 14 quarters since. The position peaked at $20.5M in Q3 2023. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Carlyle Group held 269,895 shares of OnKure Therapeutics worth $1.23M as of Q2 2026.
  • Carlyle Group left its OnKure Therapeutics share count unchanged in Q2 2026.
  • OnKure Therapeutics made up 0.01% of Carlyle Group's portfolio in Q2 2026, its #11 holding.
  • Carlyle Group first reported a position in OnKure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Carlyle Group's OnKure Therapeutics position peaked at $20.5M in Q3 2023.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.